OKYO Pharma Announces Purchase of Shares by Chief Executive Officer

Summary by AI BETAClose X

OKYO Pharma announced that its Chief Executive Officer, Robert J. Dempsey, purchased 15,000 ordinary shares on NASDAQ at $1.54 per share, representing a total investment of $23,100. This insider purchase may signal confidence in the company's future prospects, particularly as OKYO Pharma plans to initiate a global Phase 3 pivotal clinical trial in the second half of the year for its investigational therapy urcosimod, aiming to enroll approximately 111 patients for the treatment of neuropathic corneal pain.

Disclaimer*

UK 100

Latest directors dealings